background
definit
diagnosi
leishmania
infect
base
demonstr
parasit
microscop
analysi
tissu
biopsi
specimen
aspir
sampl
howev
microscopi
gener
show
low
sensit
requir
invas
sampl
method
describ
develop
simpl
rapid
test
detect
polymeras
chain
reactionamplifi
leishmania
dna
phase
evalu
text
conduct
clinic
sampl
nonendem
endem
control
subject
patient
confirm
cutan
leishmaniasi
cl
mucocutan
leishmaniasi
mcl
viscer
leishmaniasi
vl
peru
kenya
sudan
result
lower
detect
limit
assay
fg
leishmania
dna
parasit
l
blood
specif
confid
interv
ci
ci
nonendem
endem
control
sampl
respect
sensit
ci
ci
ci
lesion
patient
cl
mcl
blood
patient
vl
respect
conclus
leishmania
oligoctest
show
high
specif
sensit
clinic
sampl
abl
detect
parasit
sampl
obtain
less
invas
mean
blood
lymph
lesion
scrape
assay
promis
new
tool
simplifi
standard
molecular
detect
leishmania
parasit
leishmaniasi
vectorborn
diseas
caus
protozoa
genu
leishmania
endem
mani
area
tropic
subtrop
mediterranean
basin
clinic
present
depend
infect
speci
immun
statu
patient
rang
selfheal
skin
sore
devast
cutan
mucocutan
ulcer
lethal
viscer
form
diseas
respons
import
public
health
econom
problem
affect
region
definit
diagnosi
leishmania
infect
current
base
microscop
demonstr
parasit
skin
biopsi
specimen
mucos
aspir
sampl
cutan
leishmaniasi
cl
mucocutan
leishmaniasi
mcl
spleen
bone
marrow
aspir
sampl
viscer
leishmaniasi
vl
howev
convent
method
hamper
low
variabl
sensit
need
invas
sampl
techniqu
sensit
may
increas
prior
vitro
cultiv
parasit
techniqu
cumbersom
time
consum
serolog
test
direct
agglutin
test
dat
support
clinic
diagnosi
vl
antibodi
remain
detect
year
success
treatment
furthermor
serolog
test
less
use
patient
vl
coinfect
hiv
cl
mcl
amplif
parasit
dna
polymeras
chain
reaction
pcr
evolv
one
specif
sensit
method
leishmania
detect
despit
promis
featur
pcr
restrict
wellequip
laboratori
set
partli
due
technic
complex
dna
extract
pcr
product
detect
need
simplif
first
step
concern
visual
amplifi
dna
usual
identifi
use
electrophoresi
follow
ultraviolet
transillumin
presenc
carcinogen
ethidium
bromid
safer
nucleic
acid
stain
base
fluoresc
dye
much
expens
routin
use
laboratori
altern
method
pcr
product
detect
realtim
pcr
pcrelisa
mass
spectrometri
develop
remain
complex
expens
highli
depend
specif
equip
along
need
simplif
pcr
assay
demand
standard
optim
present
standard
pcr
leishmania
detect
larg
neglect
abund
inhous
pcr
assay
may
lead
diagnost
inconsist
oligochromatographi
provid
simpl
rapid
dipstick
format
detect
pcr
product
cori
bioconcept
patent
wo
pcr
product
visual
dipstick
hybrid
goldconjug
probe
allow
sequencespecif
pcr
product
detect
detect
format
take
min
requir
equip
water
bath
pipett
intern
control
amplif
chromatograph
migrat
incorpor
assay
techniqu
alreadi
success
appli
diagnosi
human
african
trypanosomiasi
toxoplasmosi
sever
acut
respiratori
syndrom
high
sensit
specif
report
present
develop
evalu
leishmaniaspecif
pcroligochromatograph
test
leishmania
oligoctest
target
short
sequenc
within
leishmania
rrna
gene
provid
proof
concept
experiment
sampl
evalu
phase
leishmania
oligoctest
larger
seri
clinic
sampl
nonendem
endem
control
subject
patient
cl
mcl
vl
dna
leishmania
speci
l
donovani
l
amazonensi
l
infantum
l
braziliensi
l
peruviana
l
guyanensi
l
panamensi
l
mexicana
l
major
l
lainsoni
l
tropica
l
aethiopica
trypanosoma
brucei
gambiens
trypanosoma
cruzi
obtain
dna
refer
bank
institut
tropic
medicin
antwerp
itma
dna
pathogen
sporothrix
schenckii
plasmodium
falciparum
mycobacterium
tuberculosi
schistosoma
mansoni
obtain
research
group
inform
consent
obtain
patient
guardian
person
without
diseas
human
anim
experiment
guidelin
itma
follow
ethic
clearanc
studi
obtain
institut
review
board
belgium
kenya
sudan
peru
spike
blood
l
donovani
promastigot
grown
glucoselactalbuminserumhemoglobin
medium
fetal
calf
serum
dilut
seri
parasit
rang
parasit
parasit
per
l
blood
made
fresh
blood
obtain
edta
healthi
volunt
nonspik
blood
use
neg
control
nonendem
control
dna
extract
blood
person
confirm
brucei
gambiens
infect
democrat
republ
congo
drc
confirm
p
falciparum
infect
zambia
confirm
cruzi
infect
chile
obtain
research
group
brucei
gambiens
p
falciparum
infect
confirm
direct
parasit
detect
microscopi
cruzi
infect
confirm
kinetoplast
dna
pcr
follow
southern
blot
hybrid
patient
cl
mcl
healthi
endem
control
peru
lesion
biopsi
specimen
patient
cl
mucos
aspir
sampl
patient
mcl
lesion
scrape
patient
cl
collect
instituto
de
medicina
tropic
alexand
von
humboldt
lima
peru
cl
mcl
confirm
mean
microscopi
andor
cultiv
ml
novymacnealnicol
medium
difco
laboratori
contain
defibrin
rabbit
blood
fortyon
cl
mcl
lesion
sampl
posit
direct
microscopi
result
remain
becam
posit
cultur
biopsi
specimen
obtain
activ
edg
lesion
steril
biopsi
puncher
simpl
steril
lancet
use
lesion
scrape
dental
biopsi
specimen
healthi
endem
control
subject
collect
dental
clinic
lima
peru
biopsi
specimen
lesion
scrape
store
absolut
ethanol
dna
extract
patient
vl
healthi
endem
control
kenya
sudan
sampl
collect
kenya
sudan
perform
kenya
medic
research
institut
khartoum
univers
respect
blood
sampl
patient
confirm
vl
healthi
endem
control
subject
collect
baringo
district
kenya
vl
control
sampl
gedarif
state
sudan
vl
control
sampl
patient
classifi
confirm
vl
parasit
observ
microscop
analysi
lymph
bone
marrow
aspir
sampl
sudan
spleen
aspir
sampl
kenya
person
classifi
healthi
endem
control
clinic
suspicion
vl
dat
titer
sudan
kenya
threshold
valu
use
routin
institut
along
blood
sampl
bone
marrow
lymph
remain
sudanes
patient
confirm
vl
collect
subsequ
analysi
leishmania
oligoctest
l
blood
bone
marrow
lymph
use
dna
extract
dna
spike
blood
sampl
biopsi
specimen
lesion
scrape
extract
use
qiaamp
dna
blood
mini
kit
qiaamp
dna
mini
kit
qiagen
respect
dna
blood
bone
marrow
lymph
node
sampl
patient
vl
healthi
endem
control
extract
accord
method
boom
et
al
dna
elut
l
pure
water
trisedta
te
buffer
store
except
sudanes
clinic
sampl
elut
l
te
buffer
primer
probe
ic
dna
synthes
biomersnet
figur
sequenc
rrna
gene
trypanosomatid
parasit
l
donovani
genbank
access
number
brucei
gambiens
genbank
access
number
cruzi
genbank
access
number
align
leishmaniaspecif
primer
design
use
dnaman
softwar
version
lynnon
sens
primer
antisens
primer
amplifi
sequenc
within
rrna
gene
leishmania
ic
dna
length
leishmania
target
sequenc
sequenc
ident
except
central
part
detect
probe
design
synthes
conjug
gold
particl
use
procedur
describ
patent
wo
leishmania
captur
probe
ic
captur
probe
hybrid
central
part
leishmania
amplicon
ic
dna
amplicon
respect
synthes
biotinyl
end
linker
ad
avoid
steric
hindranc
biotinavidin
bind
hybrid
migrat
control
sequenc
revers
complement
detect
probe
sequenc
pcr
mixtur
prepar
ad
l
sampl
dna
u
hotstar
taq
polymeras
qiagen
l
leishmania
amplimix
cori
bioconcept
premad
pcr
mix
contain
compon
allow
pcr
amplif
primer
ic
dna
concentr
moll
commonli
use
dttp
replac
dutp
allow
elimin
carryov
contamin
uracildna
nglycosylas
ung
initi
denatur
step
min
activ
hotstar
taq
polymeras
follow
cycl
min
min
singl
final
extens
min
amplif
done
thinwal
pcr
tube
abgen
thermocycl
biometra
prepar
leishmania
oligostrip
construct
describ
deborggraev
et
al
follow
modif
lower
absorb
pad
test
side
impregn
detect
probe
leishmania
captur
probe
lower
absorb
pad
control
side
impregn
detect
probe
ic
captur
probe
side
nitrocellulos
membran
line
coat
line
neutralit
avidin
belovo
sa
line
migrat
control
probe
principl
schemat
overview
leishmania
oligoctest
principl
present
figur
assay
repeat
control
line
indic
migrat
pcr
failur
assay
procedur
pcr
amplif
pcr
product
denatur
transfer
immedi
ice
l
mix
equal
volum
migrat
buffer
preheat
leishmania
oligostrip
dip
solut
test
result
read
min
perform
use
pcr
mix
contain
singlestrand
intern
control
ic
templat
ic
templat
amplifi
primer
leishmania
dna
target
contain
specif
intern
sequenc
dot
line
pcr
subsequ
denatur
complet
pcr
product
solut
contain
singlestrand
leishmania
ic
dna
mix
equal
volum
migrat
buffer
preheat
leishmania
oligostrip
dip
solut
test
result
read
migrat
migrat
solut
take
impregn
probe
goldlabel
detect
probe
hybrid
type
amplicon
biotinyl
leishmania
captur
probe
test
side
biotinyl
ic
captur
probe
control
side
hybrid
respect
amplicon
gold
biotin
label
indic
white
circl
black
circl
respect
biotinyl
captur
probe
accumul
hybrid
complex
neutralit
avidin
line
side
strip
result
visibl
red
line
neg
sampl
ic
amplicon
present
captur
control
side
excess
detect
probe
migrat
hybrid
complementari
probe
coat
side
dipstick
control
migrat
ic
line
migrat
control
line
determin
whether
test
valid
invalid
invis
migrat
control
line
indic
invalid
detect
step
invalid
pcr
indic
neg
ic
line
combin
neg
test
line
latter
possibl
due
inhibitori
factor
extract
dna
sampl
contain
high
concentr
leishmania
dna
competit
leishmania
dna
ic
templat
dna
pcr
result
invis
ic
control
line
combin
strongli
visibl
leishmania
test
line
case
test
consid
valid
accur
detect
parasit
utmost
import
diagnosi
leishmania
infect
diseas
control
report
develop
proofofconcept
analysi
phase
evalu
simplifi
molecular
test
detect
leishmania
organ
clinic
sampl
leishmania
oligoctest
base
pcr
amplif
leishmania
dna
follow
simpl
rapid
detect
pcr
product
dipstick
format
lower
detect
limit
assay
evalu
l
donovani
promastigot
fg
purifi
dna
parasit
l
human
blood
could
detect
fluctuat
analyt
sensit
differ
isol
might
expect
inga
et
al
report
lower
copi
number
rrna
gene
l
viannia
peruviana
southern
peru
compar
l
v
peruviana
northern
peru
studi
howev
observ
significantli
lower
sensit
leishmania
oligoctest
patient
origin
l
v
peruvianaendem
region
southern
peru
one
patient
neg
test
result
crossreact
nontarget
human
pathogen
observ
leishmania
speci
test
posit
test
result
consid
high
similar
rrna
gene
sequenc
leishmania
endotrypanum
crithidia
wallaceina
leptomona
organ
assay
might
posit
result
nonpathogen
lower
trypanosomatid
although
chanc
find
protozoa
immunocompet
patient
neglig
may
show
opportunist
infect
immunocompromis
patient
need
confirm
could
provid
direct
sequenc
pcr
product
leishmaniaspecif
point
mutat
present
author
unpublish
data
leishmania
oligoctest
show
high
diagnost
specif
test
nonendem
control
blood
sampl
person
infect
brucei
gambiens
p
falciparum
cruzi
one
brucei
gambienseinfect
person
drc
posit
leishmania
oligoctest
result
exclud
possibl
could
due
leishmania
infect
vl
occasion
report
drc
evalu
clinic
sampl
patient
confirm
cl
mcl
definit
base
microscopi
andor
cultur
collect
peru
leishmania
oligoctest
show
overal
diagnost
sensit
wherea
dental
biopsi
specimen
healthi
control
subject
neg
find
similar
observ
sensit
pcr
assay
review
direct
microscopi
lesion
show
lower
sensit
lack
posit
pcr
result
confirm
cl
mcl
lesion
sampl
might
explain
heterogen
parasit
distribut
lesion
delay
sampl
collect
test
falseposit
microscop
result
caus
stain
artifact
support
fact
leishmania
oligoctest
neg
sampl
also
neg
second
pcr
analysi
perform
peru
target
leishmania
kinetoplast
dna
author
unpublish
data
leishmania
dna
could
detect
lesion
scrape
encourag
offer
less
invas
sampl
procedur
compar
biopsi
punctur
higher
sensit
lesion
scrape
explain
lower
amount
pcrinhibit
factor
confirm
observ
garcia
et
al
report
higher
sensit
pcr
lesion
scrape
biopsi
specimen
bolivian
patient
cl
mcl
similar
sensit
method
cl
mcl
sampl
encourag
consid
gener
low
parasit
load
latter
sensit
blood
patient
confirm
vl
promis
suggest
oligoctest
contribut
significantli
less
invas
vl
diagnosi
patient
clinic
suspect
infect
posit
serolog
result
posit
leishmania
oligoctest
result
blood
might
need
undergo
invas
bone
marrow
spleen
sampl
previou
pcr
studi
found
rang
sensit
blood
lower
sensit
test
blood
sampl
sudan
versu
kenya
could
due
bia
parasit
load
experiment
differ
dna
extract
evalu
differ
type
extract
method
might
recommend
despit
low
number
avail
lymph
node
sampl
observ
show
posit
leishmania
oligoctest
result
encourag
inde
molecular
diagnosi
lymph
node
prove
high
sensit
would
major
step
forward
search
noninvas
method
diagnos
vl
previou
studi
show
similar
find
larger
number
lymph
node
sampl
studi
molecular
diagnosi
lymph
would
interest
especi
east
african
vl
major
patient
enlarg
lymph
node
two
datneg
blood
sampl
kenyan
sudanes
endem
control
subject
posit
leishmania
oligoctest
although
pcr
contamin
never
exclud
low
sensit
dat
sudan
report
posit
result
healthi
control
group
probabl
due
asymptomat
infect
vlendem
region
high
preval
asymptomat
infect
gener
treat
avail
drug
toxic
therefor
interpret
pcr
result
alway
take
account
possibl
asymptomat
infect
multipl
attempt
simplifi
speed
detect
pcr
product
report
pcrelisa
fluoresc
selfprob
amplicon
none
merg
simplic
speed
lowtech
approach
leishmania
oligoctest
combin
sensit
specif
pcr
simplic
speed
membran
oligochromatographi
detect
pcr
product
perform
min
requir
equip
except
water
bath
pipett
cost
leishmania
amplimix
compon
similar
convent
pcr
mix
cost
oligostrip
much
lower
commerci
agaros
number
sampl
global
cost
diagnosi
reduc
oligoctest
intern
amplif
control
elimin
need
addit
pcr
check
inhibit
common
drawback
pcr
diagnost
process
carryov
contamin
lead
falseposit
result
implement
dutpung
decontamin
system
singlestep
detect
format
leishmania
oligoctest
facilit
contamin
control
present
leishmania
oligoctest
selfcontain
kit
readytous
pcr
mix
dipstick
allow
qualiti
control
standard
howev
sampl
dna
extract
also
import
step
accur
molecular
diagnosi
need
standard
describ
tool
may
help
rapid
simpl
molecular
diagnosi
leishmaniasi
epidemiolog
studi
sensit
marker
infect
requir
although
current
format
directli
design
highthroughput
applic
need
phase
studi
estim
diagnost
accuraci
leishmania
oligoctest
patient
suspect
infect
posit
serolog
test
result
healthi
endem
control
patient
patholog
condit
furthermor
multicentr
studi
differ
pcr
method
evalu
sampl
would
highli
valuabl
addit
standard
oligochromatograph
format
identif
leishmania
speci
would
welcom
given
high
import
accur
speci
identif
patient
manag
diseas
control
epidemiolog
studi
recent
first
prototyp
discrimin
l
infantum
l
donovani
mean
oligochromatograph
approach
develop
laurent
gvda
hide
et
al
unpublish
data
combin
dipstick
novel
isotherm
nucleic
acid
amplif
techniqu
nucleic
acid
sequencebas
amplif
loopmedi
isotherm
amplif
may
circumv
need
thermocycl
reaction
therefor
simplifi
molecular
diagnosi
